Lungs News and Research

RSS

New PD-1 blocking antibody shows promise against advanced kidney cancer

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

5 Jun 2012

BroadcastMed to highlight new AMIGO suite at Brigham and Women's Hospital

BroadcastMed is proud to highlight the new Advanced Multimodality Image Guided Operating Room (AMIGO) suite at Brigham and Women's Hospital. AMIGO is the nation's first fully-integrated operating suite to offer intra-procedural access to an extensive range of advanced imaging modalities.

5 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Those cups of coffee that you drink every day to keep alert appear to have an extra perk - especially if you're an older adult. A recent study monitoring the memory and thinking processes of people older than 65 found that all those with higher blood caffeine levels avoided the onset of Alzheimer's disease in the two-to-four years of study follow-up. Moreover, coffee appeared to be the major or only source of caffeine for these individuals.

5 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI).

4 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).

4 Jun 2012

Study reveals why GBM is highly resistant to current chemotherapies

New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

2 Jun 2012

New evidence of important role of next-generation sequencing in cancer treatment

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced results from two studies using next-generation sequencing (NGS) to provide actionable information about genomic tumor alterations in individual patients' cancers across all solid tumor types.

2 Jun 2012

Health effects of wars in Iraq and Afghanistan on U.S. veterans

With the goal of preparing to manage the health concerns of returning U.S. veterans, the Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM), is devoting its June issue to the health effects of the wars in Iraq and Afghanistan.

2 Jun 2012

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.

2 Jun 2012

Two tumor suppressor genes function to disrupt overactive EGFR signaling

Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed resistance to these drugs and are therefore no longer responsive to drug treatment.

2 Jun 2012

LDK378 compound well-tolerated in patients with ALK+ NSCLC

A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib-the only approved ALK inhibitor. Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3.

2 Jun 2012

America's biopharmaceutical researchers work on many new approaches to fight cancer

America's biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients worldwide, according to a report released today by the Pharmaceutical Research and Manufacturers of America.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012

MEDIAN Technologies to participate in 2012 ASCO annual conference

MEDIAN Technologies, a leading medical imaging software developer and service provider for oncology clinical trials, announced today its participation in the 2012 ASCO annual conference, to be held next June 1-5, in Chicago, IL, USA.

2 Jun 2012

Scientists discover previously unrecognized signaling network disrupted in lung cancer

A team of researchers led by Dr. Goutham Narla at Case Western Reserve University School of Medicine in collaboration with scientists at Mount Sinai School of Medicine in New York, have discovered a previously unrecognized signaling network disrupted in lung cancer that can be turned back on by a novel combination of two previously approved FDA drugs.

2 Jun 2012

Smoke from cooking fires associated with cognitive deficits in children

Children exposed to open-fire cooking in developing countries experience difficulty with memory, problem-solving and social skills, according to researchers at the University of California, Riverside and Pitzer College in Claremont, Calif.

2 Jun 2012

Lungs News and Research

New PD-1 blocking antibody shows promise against advanced kidney cancer

BroadcastMed to highlight new AMIGO suite at Brigham and Women's Hospital

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Study reveals why GBM is highly resistant to current chemotherapies

New evidence of important role of next-generation sequencing in cancer treatment

Health effects of wars in Iraq and Afghanistan on U.S. veterans

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two tumor suppressor genes function to disrupt overactive EGFR signaling

LDK378 compound well-tolerated in patients with ALK+ NSCLC

America's biopharmaceutical researchers work on many new approaches to fight cancer

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

MEDIAN Technologies to participate in 2012 ASCO annual conference

Scientists discover previously unrecognized signaling network disrupted in lung cancer

Smoke from cooking fires associated with cognitive deficits in children

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News